

Jack Jumper Ant Allergy Program

FEDERATION FUNDING AGREEMENT – HEALTH

Table 1: Formalities and operation of schedule

Parties	Commonwealth Tasmania
Duration	This Schedule is expected to expire on 30 September 2029 or on completion of the initiative, including acceptance of final performance reporting and processing of final payments.
Purpose	<p>This Schedule will support the delivery of the Jack Jumper Ant Allergy Program (the Program) in Tasmania, including venom immunotherapy.</p> <p>Funding under this Schedule will support the manufacture and supply of Jack Jumper ant venom products by:</p> <ul style="list-style-type: none"> - supporting compliance with Therapeutic Goods Administration (TGA) good manufacturing practice guidelines and licensing requirements, as well as associated quality control and assurance processes - supporting the technical expertise required to manufacture venom extracts - establishing in-house microbiological testing capabilities for the new dedicated facility for manufacturing ant venom pharmaceutical products at the Royal Hobart Hospital - expanding capacity to sustain current operations and enable scalability to respond to increased manufacturing demand. <p>The Program is delivered by the Royal Hobart Hospital, the only manufacturer of venom used in immunotherapy (de-sensitisation) for patients with a life-threatening allergy to Jack Jumper ant stings. The Program is licensed by the TGA.</p>
Estimated financial contributions	The Commonwealth will provide an estimated total financial contribution to Tasmania of \$1.82 million over 3 years in respect of this Schedule. The profile for the total financial contribution is presented in Table 1.

Additional terms	<p>The Tasmanian Government continues to commit significant funding to help futureproof manufacturing, by funding the construction of a state-of-the-art facility at the Royal Hobart Hospital. The facility is specifically designed to produce Jack Jumper ant venom products under the good manufacturing practice guidelines regulated by the TGA. The Royal Hobart Hospital is licensed by the TGA to manufacture the active pharmaceutical ingredient, which is also supplied to 2 other Australian states (Victoria and South Australia) for patient treatment.</p> <p>The Tasmanian Government will ensure that the Program remains compliant with all relevant TGA regulatory requirements, including maintaining appropriate licensing for the manufacture and quality control testing of ant venom products. Continuity of supply will be maintained until completion and handover of the new facility to the Royal Hobart Hospital, followed by a transition period to allow for validation (TGA inspection) of the new facility.</p>
------------------	---

Table 1: Financial contributions to the state

(\$ million)	2026-27	2027-28	2028-29	Total
Estimated total budget	0.960	0.430	0.430	1.820
Less estimated National Partnership Payments	0.960	0.430	0.430	1.820
Balance of non-Commonwealth contributions	0	0	0	0

Note: Tasmania is contributing funding to this initiative, but the specific amount is unknown.

Table 2: Performance requirements, reporting and payment summary

Output	Performance milestones	Report due	Payment
Supporting the manufacture and supply of Jack Jumper ant venom products as part of the Royal Hobart Hospital's Jack Jumper Ant Allergy Program	Provision of a project plan outlining how Tasmania will deliver the outputs and purpose described in this Federation Funding Agreement (FFA) Schedule, including: <ul style="list-style-type: none"> - improving quality control and assurance processes - supporting the technical expertise required to manufacture venom extracts - establishing in-house microbiological testing capabilities for the new dedicated facility for manufacturing ant venom pharmaceutical products at the Royal Hobart Hospital - meeting and maintaining relevant regulatory standards (e.g. TGA) - conducting $\geq 90\%$ of required environmental microbiological tests internally, rather than outsourcing - maintaining sustainable manufacturing capacity to better meet demand, supporting increased output and improved timeliness. An output of the project plan will also include consideration of Program evaluation.	30 September 2026	\$960,000.00
	Provision of performance report for period 1 August 2026 – 30 June 2027, covering progress against the project plan and the identification and/or mitigation of any risks or issues relating to delivery of the activities under this FFA Schedule.	31 August 2027	\$430,000.00
	Provision of performance report for period 1 July 2027 – 30 June 2028, covering progress against the project plan and the identification and/or mitigation of any risks or issues relating to delivery of the activities under this FFA Schedule.	31 August 2028	\$430,000.00
	Provision of the final report activities under this FFA Schedule, including an assessment of the impacts, benefits and outcomes as at 30 June 2029. The report will include an assessment of how the purpose of the agreement has been achieved and any findings of the Program evaluation.	30 September 2029	Nil.

The Parties have confirmed their commitment to this schedule as follows:

Signed for and on behalf of the Commonwealth
of Australia by



The Honourable Mark Butler MP

Minister for Health and Ageing and the Minister for
Disability and the National Disability Insurance
Scheme

[Day] [Month] [Year]

08 September 2026

Signed for and on behalf of the
State of Tasmania by



The Honourable Bridget Archer MP

Minister for Health, Mental Health and Wellbeing

[Day] [Month] [Year]

5 October 2026